Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces the publication of a new meta-analysis of 16 studies that demonstrated the prophylactic application of PICO on surgical site incisions significantly reduced surgical site infections (SSIs), wound dehiscence and length of stay when compared to standard care.
According to the meta-analysis, using PICO with AIRLOCKTM Technology significantly reduced the rate of surgical site complications by 58% and the rate of dehiscence (wound rupturing along a surgical incision) by 26%. PICO treated patients spent half a day less in hospital on average*1.
“This is the first comprehensive meta-analysis that has assessed the benefit of a specific negative pressure wound therapy (NPWT) device on surgical site complications,” said Paolo Di Vincenzo, Senior Vice President Global Marketing, Smith & Nephew.
“It is a significant addition to the growing body of literature supporting PICO as an effective prophylactic treatment option for SSIs and helps provide important insights into optimizing clinical management strategies for preventing SSIs, which are an increasing concern for health-care providers and their patients around the world.”
The meta-analysis evaluated results from 16 peer-reviewed publications (including 10 RCTs) involving 1,863 patients and 2,202 incisions to assess the average effect of PICO Single Use Negative Pressure Wound Therapy System application across a wide variety of surgical indications, on surgical site infection (SSI), dehiscence, or length of hospital stay in comparison to standard of care.
The overall number needed to treat (NNT) to prevent one costly and potentially dangerous and painful SSI was just 14, and this was further reduced to an NNT of 5 for patients, treated with PICO, undergoing colorectal surgery.
Dr. Risal Djohan, Department of Plastic Surgery, Cleveland Clinic, USA, a PICO user, added: “This meta-analysis confirms the benefits and significant role of the PICO system. With the current available and published data, it underlines the importance of adapting the use of this advanced and novel innovation in helping to treat our patients with confidence to lower the potential incidence for surgical complications.”
The PICO Single Use NPWT system is being investigated in a number of further clinical trials worldwide. For more information about this study, please see http://www.smith-nephew.com/strugala/.
Media Inquiries: Rachel Cunningham
+44 (0)20 8995 5832
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping health-care professionals improve peoples’ lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has approximately 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com
To learn more about what we do to help reduce surgical site complications, please visit www.closertozero.com
This document may contain forward- looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward- looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health-care providers, payers, and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions, or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial, or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing, and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organization to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive, or reputational nature.
Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.
1. Strugala, V. and Martin, R. Meta- analysis of comparative trials evaluating a prophylactic single-use negative pressure wound therapy system for the prevention of surgical site complications. Surgical Infections (2017). DOI 10.1089/sur.2017.156*Meta-analysisi ncluded10RCT&6observationalstudi es.ReductioninSSI(16studiesincluded): 1839 patients (2154 incisions): PICO 5.2%; control group 12.5%; p<0.0001. Mean reduction in hospital length of stay 0.47 days (8 studies included): p<0.0001.